Luvesilocin

Clinical data
Other names	RE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamineO-glutarate;O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate;O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Routes of administration	Oral,subcutaneous injection[1][2]
Drug class	Non-selectiveserotonin receptor agonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen
ATC code	None
Legal status
Legal status	Investigational
Pharmacokinetic data
Metabolites	•4-HO-DiPT[2]
Onset of action	≤1 hour (s.c.Tooltip subcutaneous injection)[2]
Eliminationhalf-life	• Luvesilocin: 0.43–0.64 hours (s.c.Tooltip subcutaneous injection)[1][2] •4-HO-DiPT: 2.7–4.1 hours (s.c.Tooltip subcutaneous injection)[1][2]
Duration of action	3.6 hours (range ~3–4 hours) (s.c.Tooltip subcutaneous injection)[1][2]
Identifiers
IUPAC name 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number	2756001-39-3 Y
PubChemCID	162510634
ChemSpider	129909577
UNII	64JU3Z4Q2
ChEMBL	ChEMBL5425653
Chemical and physical data
Formula	C21H30N2O
Molar mass	326.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
InChI InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25) Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

Luvesilocin, also known asRE104 andFT-104, as well as4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPTO-glutarate or4-GO-DiPT), is apsychedelic drug of thetryptamine and4-hydroxytryptamine families which is under development for the treatment ofpsychiatric disorders.^[3][4] It is takenorally or bysubcutaneous injection.^[3][2]

The drug is aprodrugester of4-HO-DiPT, which acts as anon-selectiveserotonin receptor agonist including of theserotonin5-HT_2A receptor.^[5] 4-HO-DiPT produces psychedelic-like effects in animals.^[5]

Luvesilocin was first described in the literature in 2021.^[6][7] It is under development for the treatment ofpostpartum depression andtreatment-resistant depression.^{[8][9][10][11]} As of September 2025, the drug has reachedphase 2clinical trials.^[12] Aphase 3 trial is planned for 2026.^[12]

The effects of luvesilocin have beenclinically studied.^[2] It was evaluated at doses of 5 to 40 mg (equivalent to ~4–32 mg4-HO-DiPT) bysubcutaneous injection in this study.^[2] The drug was specifically assessed in terms of modifiedDrug Effects Questionnaire (DEQ) ratings, Mystical Experience Questionnaire (MEQ) ratings, andadverse effects.^[2] The meanduration of thepsychedelic experience after administration of luvesilocin at a dose of 30 mg was found to be 3.6 hours.^[2][1]

Luvesilocin is aprodrug that ismetabolized into4-HO-DiPT.^[5][13] Thismetabolite is ananalogue of theneurotransmitterserotonin and acts as anon-selectiveserotonin receptor agonist, including of theserotonin5-HT_2A receptor.^[5] Activation of the serotonin 5-HT_2A receptor is thought to be specifically responsible for thehallucinogenic effects ofserotonergic psychedelics.^{[citation needed]}

4-HO-DiPT produces thehead-twitch response, a behavioral proxy of psychedelic effects, in rodents.^[14] Indrug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drugDOM, with 5-fold lowerpotency than DOM and 2-fold lower potency thanpsilocin (4-HO-DMT).^[15]

The drug activatesbasolateral amygdala (BLA)interneurons via the serotonin 5-HT_2A receptor to enhanceGABAergicinhibition of principalneurons in the BLA, which may mediate ananxiolytic effect of suppression of learned fear (fear extinction) in rodents.^[6][16]

Given bysubcutaneous injection, theelimination half-life of luvesilocin is 0.43 to 0.64 hours and of4-HO-DiPT is 2.7 to 4.1 hours.^[2] The meanduration with thisroute at the employed dose was 3.6 hours.^[2]

Thechemical synthesis of luvesilocin has been described.^[5]

Analogues of luvesilocin include4-HO-DiPT (iprocin),4-AcO-DiPT (ipracetin),4-PrO-DiPT,4-AcO-DMT (psilacetin),4-PrO-DMT, and4-GO-DMT (RE-109), among others.

Luvesilocin was first described in the literature in 2021.^[6][7]

Luvesilocin is thegeneric name of the drug and itsINNTooltip International Nonproprietary Name.^[17] It is also known by its developmental code namesRE104 orRE-104 andFT104 orFT-104.^[3]

Luvesilocin is not acontrolled substance inCanada as of 2025.^[18]

Luvesilocin is not an explicitlycontrolled substance in theUnited States.^[19] However, it could be considered acontrolled substance under theFederal Analogue Act if intended for human consumption.

Luvesilocin is under development for the treatment ofpostpartum depression (PPD),treatment-resistant depression, and otherpsychiatric disorders.^{[3][1][20][21]} As of September 2025, it has reachedphase 2clinical trials for these indications.^[12] Aphase 3 trial is planned for 2026.^[12] The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).^[3]

• Substituted tryptamine
• List of investigational hallucinogens and entactogens
• Bretisilocin (5-fluoro-MET; GM-2505)
• CT-4201,EB-002, andMSP-1014

• Luvesilocin (RE-104) - AdisInsight
• Luvesilocin - Isomer Design

• Drugs not assigned an ATC code
• 4-Acyloxytryptamines
• Designer drugs
• N,N-Dialkyltryptamines
• Diisopropylamino compounds
• Esters
• Experimental hallucinogens
• Prodrugs
• Psychedelic tryptamines
• Secondary amino acids
• Serotonin receptor agonists

• Articles with short description
• Short description matches Wikidata
• Short description is different from Wikidata
• Drugs with non-standard legal status
• Chemical pages without DrugBank identifier
• Articles without KEGG source
• Articles containing unverified chemical infoboxes
• All articles with unsourced statements
• Articles with unsourced statements from October 2025